Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma

Clinical and Experimental Metastasis

Volumn 30, Issue 8, 2013, Pages 969-976

  Lattier, John M ^a   Yang, Hua ^a   Crawford, Susan ^b   Grossniklaus, Hans E ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY EYE CENTER   (United States)

Author keywords

Angiogenesis; Metastasis; PEDF; Stromagenesis; Uveal melanoma

Indexed keywords

COLLAGEN TYPE 3; PIGMENT EPITHELIUM DERIVED FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER SIZE; CAPILLARY DENSITY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENOTYPE; HISTOGENESIS; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STELLATE CELL; STROMAGENESIS; UVEA MELANOMA;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EYE PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MELANOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; SERPINS; SKIN NEOPLASMS; STROMAL CELLS; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS;

EID: 84890429106     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-013-9596-3     Document Type: Article

References (55)

1. Singh A et al (2011) Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 118:1881-1885
2. Damato B et al (2011) Uveal melanoma: Where are we going? US Ophthalmic Review 4(1):105-107
3. Hurst E et al (2003) Ocular melanoma: a review and the relationship to cutaneous melanoma. Arch Dermatol 139:1067-1073
4. Swerdlow A et al (1995) Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer 61:773-779
5. Vajdic C et al (2002) Sun exposure predicts risk of ocular melanoma in Australia. Int J Cancer 101:175-182
6. Singh A et al (2005) Uveal melanoma: genetic aspects. Ophthalmol Clini N. Am. 18:85-97
7. Sato T et al (2008) The biology and management of uveal melanoma. Curr Oncol Rep 10:431-438
8. Blanco PL et al (2012) Uveal melanoma dormancy: an acceptable clinical endpoint? Melanoma Res 22(5):334-340
9. Grossniklaus H et al (2013) progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. JAMA Ophthalmol 131(4):462-469
10. Lake S et al (2012) Comparison of formalin-fixed and snap frozen samples analyzed by multiplex ligation-dependent probe amplification for prognostic testing in uveal melanoma. Anat Pathol 53(6):2647-2652
11. Onken M et al (2004) Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64(20):7205-7209
12. Vaarwater J et al (2012) Multiplex ligation-dependent probe amplification equals fluorescence in situ hybridization for the identification of patients at risk for metastatic disease in uveal melanoma. Melanoma Res 22(1):30-37
13. Vidal-Vanaclocha F et al (2008) The prometastatic microenvironment of the liver. Cancer Microenviron 1(1):113-129
14. Bakalian S et al (2008) Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 14(4):951-956
15. Luzzi K et al (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153(3):865-873
16. Damato B et al (2007) Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114:1925-1931
17. Materin M et al (2011) Molecular alterations in uveal melanoma. Curr Probl Cancer 35(4):211-224
18. Harbour J et al (2010) Frequent mutation of bap1 in metastasizing uveal melanomas. Science 330:1410-1413
19. Marshall J et al (2007) Transcriptional profiling of human uveal melanoma from cell lines to intraocular tumors to metastasis. Clin Exp Met 24:353-362
20. Jager M et al (2002) HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol 63:444-451
21. Bingle L et al (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196:254-265
22. Beacham D et al (2005) Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 15(5):329-341
23. Zong L (2012) 18a-glycyrrhetinic acid down-regulates expression of type i and iii collagen via tgf-b1/smad signaling pathway in human and rat hepatic stellate cells. Int J Med Sci 9(5):370-379
24. Dawson D et al (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245-248
25. Fernández-Barral A et al (2012) Hypoxia negatively regulates antimetastatic pedf in melanoma cells by a hypoxia inducible factor-independent, autophagy dependent mechanism. PloS one 7(3):e32989
26. Ho T et al (2010) Pigment epithelium-derived factor is an intrinsic antifibrosis factor targeting hepatic stellate cells. Am J Pathol 177(4):1798-1811. doi: 10.2353/ajpath.2010.091085
27. Orgaz J et al (2009) Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma. Oncogene 28(47):4147-4161
28. Bernard A et al (2009) Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. J Biol Chem 284(16):10480-10490
29. Notari L et al (2010) Pigment epithelium-derived factor binds to cell-surface F1-ATP synthase. FEBS J 277:2192-2205
30. Notari L et al (2006) Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem 281(49):38022-38037
31. Chen L et al (2006) PEDF induces apoptosis in human endothelial cells by activating p38 MAP kinase dependent cleavage of multiple caspases. Biochem Biophys Res Commun 348(4):1288-1295
32. Volpert O et al (2002) Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 8(4):349-357
33. Cai J et al (2006) Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281(6):3604-3613
34. Zhang S et al (2006) Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37(1):1-12
35. Grippo P, Fitchev P, Bentrem D, Melstrom L (2012) Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut 61(10):1454-1464
36. Allavena P et al (2008) The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 222:155-161
37. Notari L et al (2005) Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. Invest Ophthalmol Vis Sci 46(8):2736-2747
38. Hanahan D et al (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353-364
39. Yang H et al (2006) Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model. Mol Vis 12:511-517
40. Yang H et al (2010) Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis. Invest Ophthalmol Vis Sci 51(1):28-34
41. Garcia M et al (2004) Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 64:5632-5642
42. Diaz C et al (1999) B16LS9 melanoma cells spread to the liver from the murine ocular posterior compartment (PC). Curr Eye Res 18(2):125-129
43. Dithmar S et al (2000) A new technique for implantation of tissue culture melanoma cells in a murine model of metastatic ocular melanoma. Melanoma Res 10(1):2-8
44. Cornwell M et al (2003) Pigment epithelium: derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 9(6):774-780
45. Chung C et al (2008) Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol 48:471-478
46. Yang H et al (2008) In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases. Melanoma Res 18(2):95-103
47. Yang H et al (2004) Low dose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model. Mol Vis 10:987-995
48. Foss A et al (1996) Microvessel count predicts survival in uveal melanoma. Cancer Res 56:2900-2903
49. Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133:3421
50. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6):15-18
51. Crosby M et al (2011) Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma. Br J Ophthalmol 95:112-117
52. Quintero M et al (2004) Hypoxia-inducible factor (HIF-1) in cancer. Eur J Surg Oncol 5:465-468
53. Rusciano D et al (1994) Murine model of liver metastasis. Invasion Metastasis 14(1-6):349-361
54. Rusciano D et al (1995) Expression of constitutively activated hepatocyte growth factor/scatter factor receptor (c-met) in B16 melanoma cells selected for enhanced liver colonization. Oncogene 11(10):1979-1987
55. Dithmar S et al (2003) Models of uveal melanoma: characterization of transgenic mice and other animal models for melanoma. In: Albert D and Polans A (ed) Ocular Oncology, CRC Press, Boca Raton, p 284-309